Serum intact fibroblast growth factor 23 in healthy paediatric population
It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children.
Main Authors: | Stanczyk Malgorzata, Chrul Slawomir, Wyka Krystyna, Tkaczyk Marcin |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2021-07-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2021-0288 |
Similar Items
-
Fibroblast Growth Factor-23—A Potential Uremic Toxin
by: Piotr Kuczera, et al.
Published: (2016-12-01) -
Protection Effect of Exogenous Fibroblast Growth Factor 21 on the Kidney Injury in Vascular Calcification Rats
by: Yu-Chen Shi, et al.
Published: (2018-01-01) -
The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
by: Bernhard Bielesz, et al.
Published: (2020-08-01) -
Intact Fibroblast Growth Factor 23 and Peripheral Vascular Complications in Patients on Hemodialysis
by: Melahat, et al.
Published: (2020-03-01) -
Fibroblast growth factor 23 levels before and after renal transplantation
by: Mohamed M El-khatib, et al.
Published: (2016-01-01)